Familial Hypercholesterolaemia in the Asia-Pacific Region

Familial hypercholesterolaemia (FH) is a genetic disorder, characterised by elevated serum LDL cholesterol levels from birth, and is the most common autosomal dominant disorder affecting up to one in 200 individuals. The majority of FH is expected to be found in the Asia-Pacific region, which comprises 58% of the global population. However, most of the countries in the region are developing nations, which may face challenges in the implementation of detection and treatment strategies. This review aims to describe the current state of FH in this region, including its clinical and genetic epidemiology, and the status of FH screening, detection and treatment. It also aims to identify gaps and strengths in care, and proposes various measures to uplift the management of FH in the Asia-Pacific region.

Authors

Institutions

Publication Details

Journal
Journal of Asian Pacific Society of Cardiology
Published
2025-09-23
DOI
https://doi.org/10.15420/japsc.2024.31
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Familial Hypercholesterolaemia in the Asia-Pacific Region

Natalie Koh Si Ya, Khung Keong Yeo, Julie Butters, Thushara Matthias et al.
Journal of Asian Pacific Society of Cardiology
Lipoproteins and Cardiovascular Health
article

Familial Hypercholesterolaemia in the Asia-Pacific Region

Natalie Koh Si Ya, Khung Keong Yeo, Julie Butters, Thushara Matthias, Jonathan Jiunn Liang Yap, Satoshi Honda, Ari Horton, Stephen James Nicholls, Junya Ako, Georgia Rejack, Hayato Tada, Ivan Olegario
article en

Abstract

Familial hypercholesterolaemia (FH) is a genetic disorder, characterised by elevated serum LDL cholesterol levels from birth, and is the most common autosomal dominant disorder affecting up to one in 200 individuals. The majority of FH is expected to be found in the Asia-Pacific region, which comprises 58% of the global population. However, most of the countries in the region are developing nations, which may face challenges in the implementation of detection and treatment strategies. This review aims to describe the current state of FH in this region, including its clinical and genetic epidemiology, and the status of FH screening, detection and treatment. It also aims to identify gaps and strengths in care, and proposes various measures to uplift the management of FH in the Asia-Pacific region.

Journal of Asian Pacific Society of CardiologyVol. 4
Kanazawa University (JP), University of Sri Jayewardenepura (LK), National Cerebral and Cardiovascular Center (JP), TDK (Singapore) (SG), Duke-NUS Medical School (SG), National Heart Centre Singapore (SG), Monash University (AU), Kitasato University (JP)
Amgen, AstraZeneca, Sanofi, Boston Scientific Corporation, Abbott Vascular, Daiichi Sankyo Europe
Openalex Percentile: Top 58%
Lipoproteins and Cardiovascular Health
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.